Towa Pharmaceutical Co., Ltd. (TWAPF)
| Market Cap | 1.27B +20.6% |
| Revenue (ttm) | 1.72B +5.4% |
| Net Income | 33.02M -72.3% |
| EPS | 0.67 -72.4% |
| Shares Out | n/a |
| PE Ratio | 38.48 |
| Forward PE | n/a |
| Dividend | 0.52 (2.00%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 100 |
| Open | 26.00 |
| Previous Close | 25.71 |
| Day's Range | 26.00 - 26.00 |
| 52-Week Range | 25.71 - 26.00 |
| Beta | -0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Towa Pharmaceutical
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In ... [Read more]
Financial Performance
In fiscal year 2026, Towa Pharmaceutical's revenue was 273.71 billion, an increase of 5.44% compared to the previous year's 259.59 billion. Earnings were 5.25 billion, a decrease of -72.35%.
Financial numbers in JPY Financial StatementsNews
Towa Pharmaceutical upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Jaeheon Lee upgraded Towa Pharmaceutical (TWAPF) to Overweight from Equal Weight with a price target of 5,600 yen, up from 4,500 yen, citing clearer earnings growth potential…